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Abstract
Background: BH3 mimetics are a class of drugs that antagonize the Bcl-2 family of apoptosis inhibitors. We have
previously shown that these compounds can potentiate the activity of carboplatin against several ovarian cancer
cell lines. However, recent clinical studies have highlighted that BH3 mimetics which antagonise Bcl-XL are
associated with significant thrombocytopenia. This has led to the development of ABT-199 which specifically
inhibits Bcl-2. Unfortunately, Bcl-XL appears to be more frequently deregulated in ovarian cancer than Bcl-2. We
therefore compared the ability of ABT-199, and the Bcl-XL selective compound WEHI-539, to potentiate the activity
of carboplatin in ovarian cancer cell lines.
Methods: WEHI-539, ABT-737 and ABT-199 were tested in combination with carboplatin using a panel of 6 ovarian
cancer cell lines. The activity of the drugs was evaluated using cell growth assays, staining with trypan bue and
measurement of apoptosis by measuring caspase 3/7 activity, PARP cleavage and annexin-V/propidium iodide staining.
Results: We found that WEHI-539 and ABT-737, but not ABT-199, were synergistic with carboplatin in cell growth assays
and potentiated cell death when assessed by trypan blue staining. Furthermore, WEHI-539 and ABT-737 augmented
carboplatin induced caspase 3/7 activity, PARP cleavage and annexin V labelling, but ABT-199 failed to do so.
Conclusions: These observations suggest that compounds which target Bcl-XL are necessary if BH3 mimetics are to be
successfully used to treat patients with ovarian cancer and this highlights the need to develop strategies to minimize
thrombocytopenia induced by such compounds.
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Background
Ovarian cancer (OC) is a heterogeneous disease character-
ized by low incidence, affecting around 4 % of women, but
with rapid progression and high mortality rate [1]. Al-
though many strategies have been developed to improve
the treatment of OC, it is still the fifth leading cause of
death in females with cancer. Patients with OC are often
diagnosed late in the course of the disease because the
symptoms are subtle and women frequently remain un-
aware of the disease until it reaches advanced stages [2].
The standard treatment of OC involves cytoreductive sur-
gery followed by platinum-based combination therapy.
Although most patients respond to this therapy, the devel-
opment of chemoresistance prevents long-lasting treat-
ment for OC patients and only 40 % of patients survive
5 years after diagnosis with advanced disease [3, 4].
Advances in understanding of the molecular basis of
chemoresistance and inefficient apoptosis are of great
importance for the development of targetted therapeutic
approaches that might lead to better outcomes than con-
ventional methods alone [5].
One of the major causes for the development of drug
resistance is faulty apoptosis, one cause of which is over-
expression of anti-apoptotic members of Bcl-2 family
[6]. The contribution of Bcl-2 family proteins to the
emergence of drug resistance has made them attractive
targets for the development of new therapies to treat
OC. The intrinsic apoptosis pathway is regulated by the
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Bcl-2 family of proteins. Bcl-2, Bcl-XL, Bcl-W, Mcl-1,
and Bcl-2A1 act as inhibitors of this pathway by se-
questering other pro-apoptotic family members [7–9].
BH3-mimetics are a class of compound that bind to
the apoptosis inhibitors, preventing them from bind-
ing the pro-apoptotic proteins and thereby potentiat-
ing apoptosis [10]. In addition to overcoming drug
resistance by promoting apoptosis, BH3 mimetics also
induce autophagy. This is mediated through several
mechanisms, including the liberation of the autophagy
regulator Beclin from Bcl-2 family proteins [11]. Au-
tophagy has been linked to both cell survival and cell
death and so BH3 mimetics may also modulate the
effect of cytotoxic agents through this pathway. The
most prominent drugs in this class are ABT-737, and
its closely related orally bioavailable counterpart navi-
toclax (ABT-263). Both of these compounds can in-
hibit Bcl-2, Bcl-XL and Bcl-W but not Mcl-1 [12, 13].
We have shown that both these compounds can potenti-
ate apoptosis induced by carboplatin using in vitro and
xenograft models of ovarian cancer [14, 15]. Although
navitoclax has progressed to clinical trials and there have
been initial signs of efficacy in some cancers, navitoclax
also produced dose dependent thrombocytopenia by an-
tagonizing the survival function of Bcl-XL in platelets [16].
As a result of this, ABT-199 (venetoclax) was developed
by re-engineering navitoclax to produce a drug which se-
lectively inhibits Bcl-2 protein but not Bcl-XL. Clinical
studies have demonstrated that ABT-199 does not cause
significant thrombocytopenia and its efficacy is currently
being evaluated in a number of cancer types [17–19]. This
led us to consider whether ABT-199 would also be effect-
ive in ovarian cancer. In our initial studies we noted that
Bcl-2 is not widely expressed in ovarian cancer cell lines
and this has also been observed in clinical samples [20].
This is also confirmed by interrogation of the cancer gen-
ome atlas which reports Bcl-2 is amplified or mRNA up-
regulated in less than 3 % of cases [21]. In contrast, the
proportion of cases in which amplification or mRNA up-
regulation of Bcl-XL (14 %), Bcl-W (12 %), or Mcl-1
(14 %) is observed is notably higher. This led us to ques-
tion whether a Bcl-2 selective inhibitor would be of thera-
peutic use in a significant proportion of ovarian cancer
patients. Instead, we hypothesized that a Bcl-XL selective
inhibitor would be preferable, although additional strat-
egies would be necessary to overcome the likely ensuing
thrombocytopenia. WEHI-539 is a recently described se-
lective inhibitor of Bcl-XL. We therefore compared the
ability of ABT-199 and WEHI-539 to potentiate the activ-
ity of carboplatin. ABT-737, which antagonises Bcl-2, Bcl-
XL and Bcl-2, was included as a comparator. In several
models, we found that WEHI-539, as well as ABT-737,
augmented the activity of carboplatin but ABT-199 failed
to do so. These observations suggest that compounds
targeting Bcl-XL will be of benefit in ovarian cancer,
but novel strategies to minimize thrombocytopenia
will be necessary.
Methods
Ovcar-8, Ovcar-3, Ovcar-4 and Ovsaho cells were grown
in the RPMI, Igrov-1, Cov-362 and Cov-318 cells were
grown in DMEM and Fuov-1 cells were grown in
DMEM/F-12 nutrient mixture. Growth medium were
supplemented with 10 % FCS, L-Glutamine (2 mM) and
penicillin-streptomycin (50 IU/ml). For Ovcar-3, cells
the medium was further supplemented with Insulin
(0.01 mg/ml) and sodium pyruvate (0.11 g/l). ABT-737,
ABT-199 and WEHI-539 (Medchem Express, NJ, USA),
were prepared as a 20 mmol/L solution in dimethyl sulf-
oxide, whereas the stock solution of carboplatin was pre-
pared in phosphate-buffered saline (PBS) at 13.5 mmol/L.
For cell growth assays, cells were plated in 96 wells
plate (5,000 cells/well for all cell lines except Ovcar-8
which was plated at a density of 2,500 cells/well). The
next day, cells were treated with drugs. After 72 h the
culture medium was removed and the cells were fixed
with 100 μl of cold 10 % Trichloroacetic acid (TCA),
incubated on ice for 30 min and stained with 0.4 % sul-
forhodamine B (SRB) as described [14]. The data were
analysed by using Graphpad Prism 4 software. Non-
linear regression was used to fit a four parameters Hill
equation. For drug combinations studies the cells were
exposed simultaneously to a range of concentrations of
carboplatin combined with fixed concentration of BH3
mimetics that was expected from the single agent studies
to cause 5 % growth inhibition: ABT-737, 1 μM in
Ovcar-8, Ovcar-3 and Igrov-1, 2 μM in Ovcar-4 and
Ovsaho and 6 μM in Cov-362; ABT-199, 1 μM in Ovcar-
4, 2 μM in Ovcar-3, Igrov-1, Cov-362 and Ovsaho and
3 μM in Ovcar-8; WEHI-539, 0.2 μM in Igrov-1, 0.3 μM
in Ovcar-8, 1 μM in Ovcar-3 and Ovsaho, 3.1 μM in
Cov-362 and 5 μM in Ovcar-4. Surviving cell number
was assessed by SRB staining as describe above. A com-
bination index (CI) was calculated as described by using
Chou and Talalay [22, 23].
To assess viability using trypan blue, cells were plated in
12 well plates and exposed to the indicated drug concen-
tration for 48 h except for Ovcar-4 which was assessed
after 24 h. The supernatant was collected and adherent
cells detached with trypsin. The two samples were com-
bined, and cells collected by centrifugation (150 × g,
3 min) before re-suspending in 0.2 % trypan blue in PBS
and counting live and dead cells on a haemocytometer.
To quantify apoptosis, cells were plated in 96 well
plates and exposed to the indicated concentration of car-
boplatin and/or BH3 mimetic as described above. After
48 h, 25 μl of Caspase 3/7 Glo-reagent (Promega) was
added and luminescence measured after 30 min. The
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Bliss independence criterion [24, 25] was used to calcu-
late the expected effect of drug combinations.
E x; yð Þ ¼ E xð Þ þ E yð Þ – E xð Þ  E yð Þ
Where E is the expected effect of the combination and
E(x) and E(y) are the effect of individual drugs.
To measure PARP cleavage, cells were seeded in 12
wells plate and treated with drugs and collected as de-
scribed above. After washing with PBS, cells pellets were
lysed with RIPA buffer (3 ml) comprising 20 mM Hepes,
150 mM NaCl, 2 mM ethylenediamine tetra-acetic acid,
0.5 % sodium deoxycholate, 1 % Nonidet-P40, and supple-
mented with 0.12 mM leupeptin, 0.05 mM pepstatin and
1 mM phenylmethylsulfonyl fluoride. Proteins concentra-
tion was estimated with a bicinchoninic acid (BCA) assay.
Samples (10 μg) were analysed on 4-20 % Hepes gels
(NuSep), electro-transferred to polyvinyldifluoride and
analysed with PARP antibody (Cell Signalling Technology
#9541, 1:2000).
To measure annexin V labelling, cells were seeded in 12
well plates, exposed to the indicated drug concentration
for 48 h. The cells were labelled using a Annexin V-FITC
kit (Miltenyi biotech) according to the manufactur’s in-
structions and analysed by flow cytometry.
Results
Prior to evaluating drug combinations of carboplatin
and the BH3 mimetics, the expression of Bcl-2 family
members and the single agent activity of ABT-737, ABT-
199 and WEHI-539 in cell growth assays were first de-
termined. We measured the expression of Bcl2 family
members in 8 ovarian cancer cell lines (Fig. 1), This
included three ovarian cancer cell lines Ovcar-3, Ovcar-
8 and Igrov-1 in which we have previously observed
synergy between carboplatin and ABT-737. These were
supplemented with 5 additional cell lines that have re-
cently been shown to closely resemble the profile of high
grade serous ovarian cancer [26]. Bcl-XL was expressed
in all 8 cell lines. Bcl-2 expression was more variable, al-
though it was detectable in 5 lines it was only prominent
in 3 cell lines. Mcl-1 expression was also notable in 5
cell lines. In cell growth assays, all three compounds
inhibited the growth of cultures of each cell line with
microMolar potencies (Table 1).
To evaluate which of the BH3 mimetics was synergis-
tic with carboplatin, drug combination studies were per-
formed in 6 cell lines using a fixed concentration of each
BH3 mimetic and a range of concentrations of carbopla-
tin. ABT-737 (which inhibits Bcl-2 as well as Bcl-XL)
was synergistic with carboplatin in three cell lines
(Fig. 2); this included Igrov-1 and Ovcar-8, cells in which
we have previously observed synergy [14] as well as
Cov-362. We have also previously reported synergy in
Ovcar-3 cells [14] and the results obtained here were
not inconsistent with that but did not reach statistical
significance. The Bcl-XL selective compound WEHI-539
was also synergistic with carboplatin in these cell lines. In
Ovcar-4 and Ovsaho, synergy between ABT-737 and car-
boplatin was not observed. In contrast, the Bcl-2 selective
compound ABT-199 was not synergistic with carboplatin
in any of the cell lines and was even antagonistic with car-
boplatin in Ovcar-8, Igrov-1 and Ovsaho cells.
To confirm these results, the effects of the drug combi-
nations on cell viability were assessed using trypan blue
staining (Fig. 3). Consistent with the results obtained in
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Fig. 1 a. Expression of Bcl-2 family members. Lysates were prepared from the indicated cell lines and the expression of Bcl-2 family proteins
determined by immunoblotting. The experiment shown is representative of 3 experiments. b. The western blots shown in Fig. 1a were quantified
by normalizing the signal intensity of each band to that of GAPDH in the cell line and in the same blot (mean ± S.D., n = 3)
Abed et al. Journal of Ovarian Research  (2016) 9:25 Page 3 of 9
the cell growth assays with Ovcar-8, Igrov-1 and Cov-362
cells, as well as with Ovcar-3 cells, combinations of carbo-
platin and ABT-737 or WEHI-539 killed significantly
more than the expected effect of the combination calcu-
lated from the Bliss independence criterion and the effect
of the single agents. We also observed supra-additive ef-
fects of carboplatin and ABT-737 or WEHI-539 in Ovsaho
cells, despite the fact we did not observe synergy in these
cells in cell growth assays. Notably, Ovsaho cells express a
relatively high level of Bcl-XL compared to Mcl-1 (Fig. 1).
In contrast, supra-additive effects were not observed with
ABT-199 and carboplatin in any of the cell lines and in 3
cell lines, (Ovcar-8, Igrov-1 and Ovsaho) the ABT-199
and carboplatin drug combination were antagonistic
because significantly fewer dead cells were observed
than expected.
In addition to the effect in cell growth assays, we have
previously shown that ABT-737 and navitoclax potenti-
ate apoptosis induced by carboplatin. To investigate the
effect of the selective BH3 mimetics we measured cas-
pase activity, PARP cleavage and Annexin V/Propidium
iodide staining. The activation of caspase 3/7 by the
drug combinations (Fig. 4) was reminiscent of the activ-
ity fo the cells in the foregoing studies. In 5 of the 6 of
the cell lines, the combinations of carboplatin with ei-
ther ABT-737 or WEHI-539 increased caspase-3/7 activ-
ity insignificantly more than the combined effect
expected from applying the Bliss indepedance criterion
to the effect of the single agents. In Ovcar-4 cells, cells
which expressed relatively low levels of Bcl-XL (Fig. 1)
and in which synergy was not observed in cell growth
assays (Fig. 2), the effect on caspase-3/7 activity of com-
binations of ABT-737 or WEHI-539 with carboplatin did
not differ significantly from additivity. In contrast to
ABT-737 and WEHI-539, synergistic effects were not
observed with combinations of ABT-199 and carboplatin
in any of the cells and antagonistic effects were observed
in Ovcar-8 and Ovcar-3 cells.
In Ovcar-3, Ovcar-8, Igrov and Cov-362 cells, the BH3
mimetics did not induce noticeable PARP cleavage when
they were tested as single agents (Fig. 5). As a single
agent ABT-199 only induced PARP cleavage in Ovcar-4
cells and it is noteable that these cells expressed the least
amount of Bcl-XL (Fig. 1). ABT-737 and WEHI-539 as
single agents caused noticeable PARP cleavage in Ovcar-
4 and Ovsaho cells and noteably, Ovsaho cells expressed
a relatively high ratio of Bcl-XL compared to MCl-1
(Fig. 1). When used in combination, ABT-737 and
WEHI-539 potentiated PARP cleavage induced by carbo-
platin; this was most prominent in the cells where syn-
ergy with carboplatin was observed in cell growth,
Table 1 Activity of ABT-737, ABT-199 and WEHI-539 in ovarian
cancer cell lines cell growth assays. Cells were treated with the
indicated BH3 mimetic for 72 h and surviving cell number
estimated by staining with SRB. The results are expressed as
mean ± S.D. of the number of experiments shown in parentheses
IC50 (μM)
Cell line ABT-737 ABT-199 WEHI-539
OVCAR-8 11 ± 5 (12) 18 ± 6 (13) 9 ± 5 (11)
OVCAR-3 10 ± 4 (11) 15 ± 5 (12) 9 ± 4 (14)
IGROV-1 11 ± 1 (12) 14 ± 8 (14) 16 ± 12 (12)
COV-362 17 ± 3 (10) 4 ± 2 (9) 12 ± 2 (9)
OVCAR-4 14 ± 5 (8) 15 ± 2 (7) 26 ± 9 (7)
OVSAHO 7 ± 1 (10) 17 ± 9 (6) 14 ± 1 (6)
COV-318 20 ± 3 (5) 24 ± 2 (3) 23 ± 5 (3)
FUOV-1 13 ± 1 (4) 14 ± 6 (3) 27 ± 4 (3)
Fig. 2 Evaluation of drug combinations in cell growth assays. The indicated cells were treated with combinations of carboplatin and the
indicated BH3 mimetic. After 72 h, the surviving cell number was estimated by staining with SRB. Combination indices (mean ± S.D., n = 3) at
fraction affected = 0.5 were significantly different from CI = 1.0 where indicated (paired t-test, *P ≤ 0.05 and **P ≤ 0.01.)
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Fig. 3 The effect of BH3 mimetic combinations on cell viability. The indicated cells were treated for 48 h (24 h for Ovcar-4) with carboplatin
(66 μM), the indicated BH3 mimetic (concentraions are described in Methods) or a combination of the drugs as shown. Cells were stained with
trypan blue and the percentage of dead cells determined by microscopy. Data are expressed as the fraction of viable cells measured in cells
treated with drug vehicle (mean ± SD, n = 3). The horizontal solid lines on the bar chart indicate the expected effect of the combination calculated
using the Bliss independent effect and the effect of the single agents. Experimental results are significantly different from Bliss expected effect where
indicated (*P≤ 0.05 and **P≤ 0.01, paired t-test)
Fig. 4 The effect of BH3 mimetic combinations on caspase 3/7 activity. The indicated cells were exposed to 66 μM of carboplatin in all cell lines or the
indicated BH3 mimetic (as described in Methods) for 48 h (24 h for Ovcar-4) and the caspase activity then measured. The results (mean ± S.D., n = 3)
were expressed as a fraction of the caspase activity measured in cells treated with carboplatin alone and were normalized to surviving cell number
estimated by staining with SRB. The results were significantly different where indicated (*, P < 0.05, paired t-test) from the expected effect of the drug
combination indicated with an horizontal solid line and calculated from the Bliss independence criterion and the effect of the single agents
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trypan blue or caspase assays. In Ovcar-4 cells, the com-
bination of carboplatin and ABT-737 induced very sig-
nificant PARP cleavage, but in these cells the single
agents also caused significant cleavage (Fig. 5). In con-
trast to ABT-737 and WEHI, ABT-199 failed to augment
carboplatin-induced PARP cleavage.
Flow cytometry experiments assessing annexin V/pro-
pidium iodide staining (Fig. 6 and Table 2) showed that
BH3 mimetics induced apoptosis in a manner consistent
with the caspase and PARP cleavage assays. ABT-737
and WEHI-539 combined with carboplatin induced
supra-additive staining in Ovcar3, Ovcar-8, Igrov and
Cov-326 cells, whereas the effect of ABT-199 and carbo-
platin combinations did not differ significantly from that
expected if the drugs acted additively.
Discussion
Dysregulation of apoptosis is regarded as one of the
major contributors to drug resistance, which may result
from overexpression of the anti-apoptotic Bcl-2 proteins
[27, 28]. Targeting these proteins with drugs that can ef-
fectively bind to and inactivate them provides a promis-
ing strategy for improving the quality of treatment,
especially when combined with standard anti-cancer
drugs [26]. We have previously shown that ABT-737 and
navitoclax, BH3 mimetics which can inhibit both Bcl-2
and Bcl-XL, potentiate the activity of carboplatin in ovar-
ian cancer cell lines [14, 15]. In this study, we have com-
pared the ability of the Bcl-2 and Bcl-XL selective
compounds ABT-199 and WEHI-539 to potentiate the
activity of carboplatin. WEHI-539 was synergistic with
carboplatin in several cell lines using several assays includ-
ing cell growth, cell death, activation of caspase 3/7, PARP
cleavage and Annexin V/propidium iodide staining. In
contrast, in the same set of assays, ABT-199 did not po-
tentiate the cell death induced by carboplatin and was
even mildly antagonistic with carboplatin in some assays.
The observation that ABT-199 is antagonistic with
carboplatin in several ovarian cancer cell lines is con-
cerning because this compound is undergoing clinical
evaluation as an alternative to navitoclax, a BH3 mimetic
pharmacologically similar to ABT-737 and which causes
thrombocytopenia. The reason for antagonism between
carboplatin and ABT-199 that was observed in several
cell lines is unclear. Antagonism was most evident in
Ovcar-3, Ovcar-8 and Igrov-1 cells which express rela-
tively low amounts of Bcl-2. Additivity was observed be-
tween carboplatin and ABT-199 and carboplatin in
Ovcar-4 cells and COV-362 cells which expressed higher
levels of Bcl-2. Bcl-2 has been linked to regulation of the
Fig. 5 The effect of BH3 mimetic combinations on PARP cleavage . The indicated cells were exposed to 66 μM carboplatin or the indicated BH3
mimetic for 48 h (doses as indicated in Methods) and PARP cleavage assessed by immunoblotting. The results are representative of 3 experiments
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cell cycle and DNA damage responses [29, 30] and this
may contribute to the antagonism with carboplatin. Al-
ternatively, this may represent inhibition by ABT-199 of
a target other than Bcl-2. Whatever the mechanism, any
clinical evaluation of ABT-199 and carboplatin in com-
bination should only be pursued with caution.
Synergy between ABT-737 or WEHI-539 and carbo-
platin was observed in several cell lines using several dif-
ferent assays. The pre-eminent exception to this was
Ovcar-4 cells, where the combinations of these were
additive in all the cell lines we tested. It is noteable that,
of all the cell lines evaluated, Ovcar-4 express the low-
erst level of Bcl-XL, which is inhibited by both ABT-737
and WEHI-539. It is also noteable that in this cell line
ABT-737 and WEHI-539 induced apoptosis when they
were tested as single agents. Thus, the lack of synergy
between carboplatin and these compounds in Ovcar-4
cells may reflect the low level of Bcl-XL expression
Fig. 6 The effect of BH3 mimetic combinations on annexin V/propidium iodide staining. Ovcar-8 cells were exposed to 66 μM carboplatin or the
indicated BH3 mimetic (at the concentration indicated in the Methods section) for 48 h, the cells were labelled with annexin V and propidium iodide
and assessed by flow cytometery. The results shown are representative of 3 experiments. The results with other cell lines are summarized in Table 2
Table 2 The effect of BH3 mimetic combinations on annexin V/propidium iodide staining
Annexin V/PI positive cells (% of total)
OVCAR-8 OVCAR-3 IGROV-1 COV-362 OVCAR-4 OVSAHO
Control 3 ± 1 4 ± 2 5 ± 1 2 ± 1 5 ± 2 2 ± 1
Carboplatin 11 ± 2 10 ± 3 15 ± 5 3 ± 1 75 ± 9 3 ± 2
ABT-737 6 ± 2 8 ± 1 5 ± 1 2 ± 1 17 ± 11 5 ± 1
ABT-199 4 ± 2 4 ± 1 5 ± 2 2 ± 1 8 ± 6 2 ± 1
WEHI-539 5 ± 2 6 ± 2 12 ± 5 2 ± 1 13 ± 9 6 ± 1
CbPt + ABT-737 72 ± 3** 58 ± 4* 39 ± 7 17 ± 5** 88 ± 4 4 ± 1
CbPt + ABT-199 13 ± 1 12 ± 7 16 ± 4 4 ± 1 84 ± 3 2 ± 1
CbPt +WEHI-539 79 ± 2** 71 ± 10* 35 ± 6 14 ± 2** 88 ± 5 5 ± 2
The indicated cells were exposed to 66 μM carboplatin or the indicated BH3 mimetic for 48 h, the cells were labelled with annexin V and propidium iodide and
assessed by flow cytometery. The percentage of cells that stained positive with both annexin V and propidium iodide is shown. This was significantly different
where shown paired t-test, *, P < 0.05; **, P < 0.01) from the percentage of annexinV/propidium iodide positive cells expected from the activity of the single agents
and calculated from the Bliss independence criterion
Abed et al. Journal of Ovarian Research  (2016) 9:25 Page 7 of 9
which allows these BH3 mimetics to induce apoptosis
on their own, so synergy is not readily observed.
Our data strongly support the argument that drugs
which inhibit Bcl-XL will be necessary if BH3 mimetics
are to be successfully used in the treatment of ovarian
cancer. This is reinforced by the more frequent deregu-
lation of Bcl-XL than Bcl-2 in ovarian cancer reported in
the cancer genome atlas [21]. Consequently, we consider
that the Bcl-2 selective compound ABT-199 is unlikely
to be efficacious in most ovarian cancers. However, it
may be useful in the small fraction of ovarian cancer pa-
tients that express high levels of Bcl-2 [21]. A personal-
ized medicine approach is likely to be necessary to use
ABT-199 in ovarian cancer and measurement of Bcl-2
expression in patients’ tumours seems advisable, particu-
larly in light of the antagonism we have observed in
some cell lines. Navitoclax, which has undergone clinical
evaluation in several cancers, inhibits Bcl-2, Bcl-XL and
Bcl-w and consequently it is likely to be effective in po-
tentiating the activity of carboplatin in a larger propor-
tion of ovarian cancer patients than ABT-199. However,
navitoclax has been closely linked to thrombocytopenia.
The same may be anticipated with WEHI-539 because
both drugs inhibit Bcl-XL that promotes platelet survival.
A therapeutic window may be found by careful dose es-
calation studies, Alternatively, novel strategies may be
necessary to minimize this adverse effect. For example,
encapsulation of ABT-737 in nanoparticles has been
shown to enhance its anti-tumour effects while minimiz-
ing thrombocytopenia [31]. Alternatively, we have shown
more than additive effects when paclitaxel, which is
known to have “platelet sparing” properties, is combined
with navitoclax and carboplatin [15]. This may create an
adequate therapeutic window to allow the use of navito-
clax in ovarian cancer.
Conclusion
We conclude that navitoclax remains the preferred BH3
mimetic for the treatment of ovarian cancer, but strat-
egies to minimize thrombocytopenia will be essential if
this drug is to be used safely.
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